“COMPARATIVE STUDY OF INTRATHECAL ISOBARIC ROPIVACAINE (0.75%) WITH BUPRENORPHINE AND ISOBARIC ROPIVACAINE (0.75%) WITH CLONIDINE IN PATIENTS UNDERGOING LOWER LIMB AND LOWER ABDOMINAL SURGERIES UNDER SUBARACHNOID BLOCK: A Prospective Randomised Double- blind study ?

“COMPARATIVE STUDY OF Intrathecal Isobaric Ropivacaine (0.75%) With Buprenorphine and Isobaric Ropivacaine (0.75%) With Clonidine in PATIENTS UNDERGOING LOWER LIMB ORTHOPEDIC SURGERIES AND LOWER ABDOMINAL SURGERIES UNDER SUBARACHNOID BLOCK: A PROSPECTIVE RANDOMIZED DOUBLE- BLIND STUDY ? - COMPARATIVE STUDY OF INTRATHECAL ISOBARIC ROPIVACAINE (0.75%) with BUPRENORPHINE and ISOBARIC ROPIVACAINE (0.75%) with CLONIDINE In Patients Undergoing Lower Limb and Lower abdominal surgeries UNDER

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/02/062242

Enrollment

Registered

2024-02-05

Start date

Unknown

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: INTRATHECAL ISOBARIC ROPIVACAINE (0.75%) WITH BUPRENORPHINE: INTRATHECAL ISOBARIC ROPIVACAINE (0.75%) 3.5 ml WITH BUPRENORPHINE 0.2 ml under subarachnoid block Control Intervention1: I

Eligibility

Inclusion criteria

Inclusion criteria: 1. American Society of Anesthesiologists (ASA) grade I-III 2. Age group between 18-60 years of both sexes. 3. Scheduled for Elective and emergency lower limb orthopedic AND ABDOMINAL surgeries under Spinal Anaesthesia.

Exclusion criteria

Exclusion criteria: 1. Patient refusal 2. History of allergy to study drugs 3. Post spinal surgeries, Spinal Deformities, skin sepsis in lumbar region, patients with pre-existing neurological disorders. 4. Coagulopathy, Dysrhythmia 5. Major Hepatic, Renal and Cardiovascular Dysfunction 6. BMI >35, Height 7. Surgeries involving major blood loss

Design outcomes

Primary

Measure	Time frame
TO COMPARE THE DURATION OF ANALGESIA from baselineTimepoint: TO COMPARE THE DURATION OF ANALGESIA baseline to 3 hours	—

Secondary

Measure	Time frame
TO COMPARE THE ADDITIONAL ANALGESIC REQUIREMENT IN FIRST 24 HOURSTimepoint: FIRST 24 HOURS	—

Countries

India

Contacts

Public ContactDR LOKESHWARI DIVYA J

chettinad academy of research and education

drbala.srmc@gmail.com9841544566

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026